GlassScriptPhysician profile
Monique Dye
NPI 1962153064
$1,737.98
in general payments reported to CMS, 2019-2025
15 companies · $791 in 2025
The $791 reported for 2025 was more than what 83% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $230 · 2023: $309 · 2024: $408 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,508.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $501.95 | 2022-2025 | |
| Revance Therapeutics, INC. | $384.08 | 2024-2025 | Daxxify |
| Glaxosmithkline, LLC. | $355.30 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $146.36 | 2025 | Ozempic |
| Pfizer INC. | $68.82 | 2024-2025 | |
| Grt US Holding, INC. | $52.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.03 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $37.86 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Nevro Corp. | $34.37 | 2023 | Senza |
| Catalyst Pharmaceuticals, INC. | $22.86 | 2024 | |
| Astellas Pharma US INC | $22.34 | 2025 | Veozah |
| Teva Pharmaceuticals USA, INC. | $19.89 | 2023 | Ajovy |
| Lilly USA, LLC | $15.36 | 2024 | Mounjaro |
| Medtronic, INC. | $15.19 | 2022 | |
| Relievant Medsystems, INC. | $14.94 | 2023 | Intracept |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monique Dye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.